NCT05298995View on ClinicalTrials.gov

GD2-CAR T Cells for Pediatric Brain Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2038

Conditions
Brain Tumor, PediatricMedulloblastoma, ChildhoodEmbryonal TumorHigh Grade GliomaDiffuse Midline GliomaDiffuse Intrinsic Pontine GliomaBrain Tumor Adult
Interventions
BIOLOGICAL

GD2-CART01 (iC9-GD2-CAR T-cells)

Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose

Trial Locations (1)

00165

RECRUITING

Ospedale Pediatrico Bambino Gesù, Roma

All Listed Sponsors
lead

Bambino Gesù Hospital and Research Institute

OTHER